Edesa Biotech said that data from a late-stage study of its experimental drug for the treatment of Acute Respiratory Distress Syndrome affirmed statistically significant mortality reductions.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Why Did EDSA Stock Rally More Than 70% Today?